Bone effects of cancer therapies: Pros and cons

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 3, 2011, Pages 251-257

  Silbermann, Rebecca ^a   Roodman, G David ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Chemotherapy; Osteoblast; Osteoclast; Remodeling

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; GLUCOCORTICOID; RETINOIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE; BONE DENSITY; BONE REMODELING; DRUG EFFECT; HUMAN; NEOPLASM; OSTEOBLAST; OSTEOCLAST; REVIEW;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; BONE REMODELING; GLUCOCORTICOIDS; HUMANS; NEOPLASMS; OSTEOBLASTS; OSTEOCLASTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRETINOIN;

EID: 80052766482     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328349c524     Document Type: Review

References (82)

1. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80:1546-1556. (Pubitemid 27444026)
2. Pearce G, Ryan PF, Delmas PD, et al. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998; 37:292-299.
3. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010; 6:82-88. An excellent summary of the pathophysiology of glucocorticoid-induced osteoporosis, including management guidelines.
4. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2:65-73. (Pubitemid 33643893)
5. Weinstein RS, Jilka RL, Almeida M, et al. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010; 151:2641-2649.
6. Maniadaki I, Stiakaki E, Germanakis I, Kalmanti M. Evaluation of bone mineral density at different phases of therapy of childhood all. Pediatr Hematol Oncol 2006; 23:11-18. (Pubitemid 41769968)
7. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39:1383-1389. (Pubitemid 32045866)
8. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000. (Pubitemid 30350061)
9. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent highdose oral glucocorticoid therapy. Arthritis Rheum 2007; 56:208-214. (Pubitemid 46106193)
10. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 2008; 82:249-257.
11. Zorzon M, Zivadinov R, Locatelli L, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005; 12:550-556. (Pubitemid 40956813)
12. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496-1503.
13. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004; 22:1215-1221. (Pubitemid 41079834)
14. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18:1570-1593. (Pubitemid 30205404)
15. Fan C, Cool JC, Scherer MA, et al. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 2009; 44:61-70.
16. Minaur NJ, Kounali D, Vedi S, et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002; 41:741-749. (Pubitemid 34822955)
17. Inamo Y, Suzuki T, Mugishima H. A case of growth failure caused by 13-cisretinoic acid administration after bone marrow transplantation for neuroblastoma. Endocr J 1999; 46 (Suppl):S113-S115. (Pubitemid 29254498)
18. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176-S182.
19. Hobbie WL, Moab SM, Carlson CA, et al. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer 2011; 56:474-476. A small, single-institution review of existing data on bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.
20. Balkan W, Rodriguez-Gonzalez M, Pang M, et al. Retinoic acid inhibits NFATc1 expression and osteoclast differentiation. J Bone Miner Metab 2011. An in-vitro analysis of the impact of retinoic acid and isoform-specific retinoic acid receptor antagonists on osteoclastogenesis.
21. Decensi A, Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur J Cancer 2000; 36:694-709. (Pubitemid 30179740)
22. Li X, Ling W, Pennisi A, et al. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett 2009; 284:175- 181.
23. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl) retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of IkB(alpha) kinase and nuclear factorkB- regulated gene products. Cancer Res 2005; 65:9555-9565. (Pubitemid 41508026)
24. Drake MT, McCready LK, Hoey KA, et al. Effects of suppression of folliclestimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab 2010; 95:5063-5068. A prospective clinical trial comparing serum FSH levels in postmenopausal women treated with a GnRH agonist or placebo in addition to aromatase inhibitors.
25. Frenkel B, Hong A, Baniwal SK, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol 2010; 224:305-310. A comprehensive review of mechanisms by which sex steroids effect adult bone turnover and the regulation of bone mass.
26. Vestergaard P. Skeletal effects of drugs to treat cancer. Curr Drug Saf 2008; 3:173-177.
27. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 2006; 295:2727-2741.
28. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003; 26:S27-S33. (Pubitemid 36966420)
29. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-1223. (Pubitemid 44128334)
30. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011; 13:205. A thorough review of management strategies for patients on aromatase inhibitor therapy, including discussion of recent clinical data on survival outcomes of patients treated with aromatase inhibitors compared with those receiving tamoxifen alone.
31. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45-53.
32. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492. (Pubitemid 350002953)
33. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-570.
34. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-3635. (Pubitemid 46630537)
35. Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008; 13:829-837.
36. Deeks ED, Scott LJ. Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 2009; 69:889-918.
37. Aihara T, Suemasu K, Takei H, et al. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan Substudy. Oncology 2011; 79:376-381. A substudy of the TEAM Japan data on aromatase inhibitor-induced skeletal changes. Provides data on the differential effects of steroidal and nonsteroidal aromatase inhibitor skeletal effects.
38. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90:6410-6417. (Pubitemid 41759293)
39. Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006; 175:1679-1683; discussion 1683.
40. Hussain SA, Weston R, Stephenson RN, et al. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92:690-694. (Pubitemid 37475806)
41. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during longterm androgen deprivation therapy in patients with prostate cancer. Urology 2007; 69:500-504. (Pubitemid 46428384)
42. Panju AH, Breunis H, Cheung AM, et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2009; 103:753-757.
43. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009; 104:800-805.
44. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgendeprivation therapy in men with prostate cancer. Cancer 2009; 115:2388- 2399.
45. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf- 1 and receptor activator of nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135:688-692. (Pubitemid 44674080)
46. Boissy P, Andersen TL, Lund T, et al. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008; 32:1661-1668.
47. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110:334-338. (Pubitemid 47026851)
48. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22:2247- 2256.
49. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131:71-73. (Pubitemid 43899710)
50. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498. (Pubitemid 41007864)
51. Lund T, Soe K, Abildgaard N, et al. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 2010; 85:290-299. This prospective study evaluated the effect of bortezomib on osteoblast differentiation and proliferation as well as bone matrix deposition in bisphosphonate- naïve myeloma patients.
52. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-917.
53. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28:2259-2266. Long-term survival follow-up of the phase III VISTA trial, (bortezomib, melphalan, prednisone versus melphalan and prednisone in patients with previously untreated myeloma ineligible for high-dose therapy).
54. Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011; 86:372-384. An update of survival data (median follow-up of 36.7 months) from the landmark VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial, confirming the significant prolongation of OS seen with VMP treatment as compared with melphalan and prednisone.
55. Zangari M, Yaccoby S, Pappas L, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011; 96:333-336. This study evaluated bone changes (bone architecture and metabolism changes) associated with proteasome inhibitor treatment in relapsed or refractory myeloma patients.
56. McGee-Lawrence ME, Westendorf JJ. Histone deacetylases in skeletal development and bone mass maintenance. Gene 2011; 474:1-11. A thorough review of HDAC biology and summary of current understanding of how HDACs contribute to bone development and maintenance.
57. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of nonhistone proteins. Gene 2005; 363:15-23.
58. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
59. Jeon EJ, Lee KY, Choi NS, et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006; 281:16502-16511.
60. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005; 20:2254-2263. (Pubitemid 41698788)
61. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004; 279:41998-42007. (Pubitemid 39313651)
62. Hesse E, Saito H, Kiviranta R, et al. Zfp521 controls bone mass by HDAC3- dependent attenuation of Runx2 activity. J Cell Biol 2010; 191:1271-1283.
63. Razidlo DF, Whitney TJ, Casper ME, et al. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One 2010; 5:e11492.
64. Pham L, Kaiser B, Romsa A, et al. HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem 2011; 286:12056-12065. A concise summary of HDAC3 and HDAC7 effects on osteoclast differentiation.
65. Jensen ED, Gopalakrishnan R, Westendorf JJ. Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem 2009; 284:2225-2234.
66. Jensen ED, Schroeder TM, Bailey J, et al. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 2008; 23:361-372. (Pubitemid 351304666)
67. Elbaz A, Rivas D, Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology 2009; 10:747-755.
68. Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kB ligand (RANKL) activation of NF-kB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 2011; 286:11492-11505. An in-vitro study of the effects of resveratrol on RANKL during bone morphogenesis. Findings demonstrated that resveratrol-activated Sirt-1 is important for the regulation of osteoclast-osteoblast activity in bone formation.
69. Cantley M, Fairlie D, Bartold P, et al. Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro. J Cell Physiol 2011. An in-vitro evaluation of the effects of HDAC classes on human osteoclast activity. Results suggest that inhibition of both HDAC classes I and II may be required for suppression of human osteoclasts.
70. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-784. (Pubitemid 44348499)
71. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kB activation. J Biol Chem 2006; 281:5612-5622. (Pubitemid 43847658)
72. McGee-Lawrence ME, McCleary-Wheeler AL, Secreto FJ, et al. Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 2011; 48:1117-1126. An in-vivo study of SAHA's effects on bone remodeling and bone mass that includes a thorough review of preclinical literature on SAHA's other skeletal effects.
73. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-4921. (Pubitemid 34984414)
74. Piekarz RL, Frye R, Turner M, et al. Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:5410-5417.
75. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117:336-342.
76. Nakamura T, Kukita T, Shobuike T, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005; 175:5809-5816. (Pubitemid 41508065)
77. Muller C, Winter CC, Rosenbaum D, et al. Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients. BMC Musculoskelet Disord 2010; 11:287. An evaluation of BMD decrements in pediatric and adolescent Ewing's and osteosarcoma patients following completion of neoadjuvant therapy. BMD decrements were compared at the affected and nonaffected femoral neck in patients with lower extremity tumors, as well as in the lumbar spine and calcaneus.
78. Ruza E, Sierrasesumaga L, Azcona C, Patino-Garcia A. Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res 2006; 59:866-871. (Pubitemid 44297644)
79. Kaste SC, Ahn H, Liu T, et al. Bone mineral density deficits in pediatric patients treated for sarcoma. Pediatr Blood Cancer 2008; 50:1032-1038. (Pubitemid 351506356)
80. Azcona C, Burghard E, Ruza E, et al. Reduced bone mineralization in adolescent survivors of malignant bone tumors: comparison of quantitative ultrasound and dual-energy x-ray absorptiometry. J Pediatr Hematol Oncol 2003; 25:297-302. (Pubitemid 36506216)
81. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-4057. (Pubitemid 46606220)
82. Van Poznak CH, Temin S, Yee GC, et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221-1227. A comprehensive summary by ASCO on the management of bone health in patients with metastatic breast cancer.